Andrew J Armstrong1, Ping Lin2, Bertrand Tombal3, Fred Saad4, Celestia S Higano5, Anthony M Joshua6, Teresa Parli7, Brad Rosbrook8, Steve van Os9, Tomasz M Beer10. 1. Division of Medical Oncology and Urology, Duke Cancer Institute, Duke University, Durham, NC, USA. Electronic address: andrew.armstrong@duke.edu. 2. Biostatistics, Pfizer Inc., San Francisco, CA, USA. 3. Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. 4. Division of Urology and Urologic Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. 5. Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 6. Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, New South Wales, Australia. 7. Clinical Development, Pfizer Inc., San Francisco, CA, USA. 8. Biostatistics, Pfizer Inc., San Diego, CA, USA. 9. Biostatistics, Astellas Pharma Europe BV, Leiden, The Netherlands. 10. Hematology/Medical Oncology, OHSU Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA.
Abstract
BACKGROUND: In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To evaluate long-term benefits and risks of enzalutamide in the final prespecified PREVAIL analysis. DESIGN, SETTING, AND PARTICIPANTS: We conducted a final 5-yr survival analysis of PREVAIL in men with chemotherapy-naïve mCRPC from the enzalutamide (n = 689) andplacebo (n = 693) arms. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Predictors of the primary outcome of overall survival were estimated using the Kaplan-Meier method. Long-term adverse events over time were analyzed. RESULTS AND LIMITATIONS: At the 5-yr data cutoff, 1382 of 1717 (80%) men had died. Enzalutamide reduced the hazard of death by 17% (hazard ratio 0.83; 95% confidence interval [CI] 0.75-0.93; p < 0.001), despite 65%, 54%, and 43% of placebo-treated patients receiving subsequent docetaxel, abiraterone, and enzalutamide, respectively. Median overall survival was 36 mo (95% CI 34-38) in the enzalutamide arm versus 31 mo (95% CI 29-34) in the placebo arm, with a median follow-up of 69 mo. Prognostic modeling showed 5-yr survival rates of 42%, 24%, and 5% for low-, intermediate-, and high-risk groups, respectively. Greater degrees of confirmed prostate-specific antigen declines (≤3 mo) were associated with greater 5-yr survival. A higher incidence of fatal treatment-emergent adverse events was observed with enzalutamide (6.9% vs 3.8%), with an increase in fatal cardiovascular events (1.6% vs 0.4%). CONCLUSIONS: With >5 yr of follow-up, enzalutamide continued to demonstrate improved survival in patients with mCRPC despite crossover and multiple subsequent effective therapies, balanced against a slightly higher rate of fatal cardiovascular events. PREVAIL is registered on ClinicalTrials.gov as NCT01212991. PATIENT SUMMARY: We report a maintained long-term survival benefit with enzalutamide and risks with >5 yr of enzalutamide treatment and follow-up in men with metastatic prostate cancer, and identify groups of men with widely different outcomes based on clinical factors.
RCT Entities:
BACKGROUND: In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To evaluate long-term benefits and risks of enzalutamide in the final prespecified PREVAIL analysis. DESIGN, SETTING, AND PARTICIPANTS: We conducted a final 5-yr survival analysis of PREVAIL in men with chemotherapy-naïve mCRPC from the enzalutamide (n = 689) and placebo (n = 693) arms. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Predictors of the primary outcome of overall survival were estimated using the Kaplan-Meier method. Long-term adverse events over time were analyzed. RESULTS AND LIMITATIONS: At the 5-yr data cutoff, 1382 of 1717 (80%) men had died. Enzalutamide reduced the hazard of death by 17% (hazard ratio 0.83; 95% confidence interval [CI] 0.75-0.93; p < 0.001), despite 65%, 54%, and 43% of placebo-treated patients receiving subsequent docetaxel, abiraterone, and enzalutamide, respectively. Median overall survival was 36 mo (95% CI 34-38) in the enzalutamide arm versus 31 mo (95% CI 29-34) in the placebo arm, with a median follow-up of 69 mo. Prognostic modeling showed 5-yr survival rates of 42%, 24%, and 5% for low-, intermediate-, and high-risk groups, respectively. Greater degrees of confirmed prostate-specific antigen declines (≤3 mo) were associated with greater 5-yr survival. A higher incidence of fatal treatment-emergent adverse events was observed with enzalutamide (6.9% vs 3.8%), with an increase in fatal cardiovascular events (1.6% vs 0.4%). CONCLUSIONS: With >5 yr of follow-up, enzalutamide continued to demonstrate improved survival in patients with mCRPC despite crossover and multiple subsequent effective therapies, balanced against a slightly higher rate of fatal cardiovascular events. PREVAIL is registered on ClinicalTrials.gov as NCT01212991. PATIENT SUMMARY: We report a maintained long-term survival benefit with enzalutamide and risks with >5 yr of enzalutamide treatment and follow-up in men with metastatic prostate cancer, and identify groups of men with widely different outcomes based on clinical factors.
Authors: H I Scher; A J Armstrong; J D Schonhoft; A Gill; J L Zhao; E Barnett; E Carbone; J Lu; E S Antonarakis; J Luo; S Tagawa; C H Dos Anjos; Q Yang; D George; R Szmulewitz; D C Danila; R Wenstrup; M Gonen; S Halabi Journal: Eur J Cancer Date: 2021-04-21 Impact factor: 10.002
Authors: Raymond S McDermott; John Greene; John McCaffrey; Imelda Parker; Sylva Helanova; Anne-Marie Baird; Ausra Teiserskiene; Marvin Lim; Helen Matthews; Olwyn Deignan; John Feeney; Pierre G Thirion; Stephen P Finn; Paul J Kelly Journal: Ther Adv Med Oncol Date: 2021-09-06 Impact factor: 8.168
Authors: Maria Massaro; Giuseppe Facondo; Gianluca Vullo; Anna Maria Aschelter; Alessandro Rossi; Vitaliana De Sanctis; Paolo Marchetti; Mattia Falchetto Osti; Maurizio Valeriani Journal: Front Oncol Date: 2021-09-23 Impact factor: 6.244
Authors: Scott T Tagawa; Krishnan Ramaswamy; Ahong Huang; Jack Mardekian; Neil M Schultz; Li Wang; Rickard Sandin; Stanislav Lechpammer; Daniel J George Journal: Prostate Cancer Prostatic Dis Date: 2021-02-21 Impact factor: 5.455